EcoR1 Capital’s Sarepta Therapeutics SRPT Stock Holding History

EcoR1 Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,292,386	Closed	-$82.5M	–	48
2025 Q1	$82.5M	Buy	1,292,386 +522,386	+68%	+$55M	4.89%	7
2024 Q4	$93.6M	Buy	+770,000	New	+$94.4M	3.54%	10
2024 Q3	–	Sell	-1,407,322	Closed	-$222M	–	67
2024 Q2	$222M	Sell	1,407,322 -512,513	-27%	-$65.8M	6.8%	3
2024 Q1	$249M	Buy	1,919,835 +1,086,928	+130%	+$133M	6.29%	4
2023 Q4	$80.3M	Buy	+832,907	New	+$79.9M	2.09%	14
2023 Q3	–	Sell	-3,660,798	Closed	-$419M	–	59
2023 Q2	$419M	Buy	3,660,798 +661,345	+22%	+$85.3M	10.27%	3
2023 Q1	$413M	Hold	2,999,453	–	–	13.31%	2
2022 Q4	$389M	Hold	2,999,453	–	–	11.83%	2
2022 Q3	$332M	Buy	2,999,453 +131,308	+5%	+$13.2M	9.79%	3
2022 Q2	$215M	Buy	2,868,145 +798,511	+39%	+$58.7M	7.42%	3
2022 Q1	$162M	Buy	+2,069,634	New	+$158M	5.06%	5
2019 Q4	–	Sell	-189,745	Closed	-$14.3M	–	54
2019 Q3	$14.3M	Buy	+189,745	New	+$22.4M	1.8%	16

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

EcoR1 Capital's SRPT Position: Q2 2025 in Review

EcoR1 Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 1,292,386 shares — an estimated $82.5M sold.

EcoR1 Capital first reported a position in SRPT in Q3 2019 and held it in 12 quarters. The position peaked at $419M in Q2 2023. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

EcoR1 Capital reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
EcoR1 Capital sold 1,292,386 Sarepta Therapeutics shares in Q2 2025, an estimated $82.5M.
EcoR1 Capital first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 12 quarters.
EcoR1 Capital's Sarepta Therapeutics position peaked at $419M in Q2 2023.
363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.